AKANDA CORP. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.091 USD | +2.13% |
|
-6.09% | -79.34% |
| May. 01 | Akanda Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 26 | Akanda Corp. Announces Board Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | 2.62 | Sales 2023 | 2.16 | Capitalization | 1.77M |
|---|---|---|---|---|---|
| Net income 2022 | -11M | Net income 2023 | -32M | EV / Sales 2022 | 1,845,597 x |
| Net Debt 2022 | 3.41 | Net Debt 2023 | 3.92 | EV / Sales 2023 | 820,824 x |
| P/E ratio 2022 |
-0.38
x | P/E ratio 2023 |
-0.06
x | Employees | 46 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.78% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +1.01% | ||
| 1 week | -8.05% | ||
| Current month | -4.19% | ||
| 1 month | -26.18% | ||
| 3 months | -72.28% | ||
| 6 months | -78.79% | ||
| Current year | -79.77% |
1 week
0.09
0.10
1 month
0.090.19
Current year
0.090.71
1 year
0.091.22
3 years
0.09310.00
5 years
0.09310.00
10 years
0.09310.00
| Managers | Title | Age | Since |
|---|---|---|---|
Katharyn Field
CEO | Chief Executive Officer | 41 | 22-06-22 |
Charn Deol
DFI | Director of Finance/CFO | 56 | Dec. 10 |
Matt Chesler
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jay Dhaliwal
BRD | Director/Board Member | 35 | 22-06-22 |
Katharyn Field
CEO | Chief Executive Officer | 41 | 22-06-22 |
David Jenkins
BRD | Director/Board Member | 43 | 23-02-12 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 0.091 | +2.13% | 3 881 461 |
| 24-05-08 | 0.0891 | -1.55% | 3,894,653 |
| 24-05-07 | 0.0905 | -0.55% | 5,906,302 |
| 24-05-06 | 0.091 | +0.55% | 8,664,160 |
| 24-05-03 | 0.0905 | -6.60% | 12,569,654 |
Delayed Quote Nasdaq, May 09, 2024 at 09:34 am EDT
More quotes
Akanda Corp. is an international medical cannabis and wellness platform company. The Companyâs portfolio includes Canmart Ltd. (CanMart), a United Kingdom-based fully licensed pharmaceutical importer and distributor which supplies pharmacies and clinics within the United Kingdom. Canmart is a licensed importer and distributor of CBD Extraction for Medicinal Purposes (CBPMs) in the United Kingdom. CanMart holds a controlled drug license issued by the Home Office to possess and supply CBPMs in the United Kingdom. The Company's seed-to-patient supply chain also includes partnerships Cellen Life Sciences' Leva Clinic, a fully digital pain clinic in the United Kingdom. The Company also develops a Canadian farming property in British Columbia, including farming land and related operations and licenses. The Company also focuses on developing tetrahydrocannabinol (THC) and cannabinoid (CBD) facilities at this site.
| 1st Jan change | Capi. | |
|---|---|---|
| -79.77% | 755K | |
| -.--% | 339M | |
| +41.56% | 264M | |
| +31.96% | 266M | |
| +41.86% | 185M | |
| +164.74% | 152M | |
| -28.57% | 145M | |
| +47.83% | 137M | |
| -7.69% | 79.94M | |
| +50.00% | 45.2M |
- Stock Market
- Equities
- AKAN Stock